闪蒸真空热解(FVP) 4-乙酰基四唑并[1,5- a ]吡啶 5在400°C时可提供3-甲基异恶唑并[3,4- b ]吡啶 通过X射线晶体学证实其结构的6。在较高的热解温度下,不稳定异吲哚基 获得8,它以酮形式存在(1,2-二氢吡咯并[2,3- b ]吡啶-3-)8K英寸CDCl 3 溶液和烯醇互变异构体(3-羟基吡咯并[2,3- b ]吡啶)8E在二甲基亚砜。这异吲哚基 8氧化二聚为异靛蓝9,在2位发生缩合反应并与甲氧基亚甲基Meldrum的酸位于1位。FVP对应乙酰四唑并[1,5- a ]喹啉 19要复杂得多,2-(氰基苯基)乙腈 主要产品在750°C下达到30(而不是杂吲哚基)。的FVP3-乙酰基-4-叠氮喹啉 在400°C下243-甲基异唑并[4,3- c ]喹啉 如图33所示,但在较高温度下未观察到重配成杂吲哚基。
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF
申请人:EPIZYME, INC.
公开号:US20150344434A1
公开(公告)日:2015-12-03
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.